-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Hemostasis and Thrombosis Risks and Management in Vascular Anomalies

Program: Education Program
Session: Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist
Hematology Disease Topics & Pathways:
Treatment Considerations
Monday, December 9, 2024, 4:30 PM-5:45 PM

Shelley E Crary, MD, MS

Arkansas Children's Hospital, Little Rock, AR

Disclosures: Crary: CSL Behring: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Medexus: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; ASC Therapeutics: Consultancy.

OffLabel Disclosure: Sirolimus for vascular anomalies; DOACs and enoxaparin for vascular malformations

See more of: Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist
See more of: Education Program
<< Previous Presentation | Next Presentation